AstraZeneca may not be long for antibiotics; Genmab pockets $10M from J&J;

@FierceBiotech: $GSK cozies up to Five Prime for respiratory R&D. More | Follow @FierceBiotech

@JohnCFierce: Baxter gets FDA OK for hemophilia A drug -- Obizur. News | Follow @JohnCFierce

@DamianFierce:  $AZN's olaparib will trade as Lynparza, which sounds like a nice lady. | Follow @DamianFierce

@EmilyMFierce: Researchers will test blood of Ebola survivors to use as a short-term treatment option. Story | Follow @EmilyMFierce

> AstraZeneca's ($AZN) future in antibiotics may be in jeopardy. Earlier this week, a U.K. blogger speculated that the drugmaker is preparing to exit the field en masse, and the company, speaking to The Wall Street Journal, said it had no immediate plans to shake things up but will "take an opportunity-driven approach in our non-core therapeutic areas," which includes anti-invectives. Story

> Genmab has banked another $10 million milestone in its collaboration with Johnson & Johnson ($JNJ), through which the companies are developing daratumumab, a Phase III treatment for multiple myeloma. Release

Medical Device News

@FierceMedDev: New microscope offers 3D cellular images that are fast, detailed and low toxicity. More | Follow @FierceMedDev

@VarunSaxena2: Bard Q3 earnings up 41% as it focuses on Lutonix launch. Story | Follow @VarunSaxena2

@EmilyWFierce: $JNJ scores victory in first metal-on-metal hip implant case to go to trial. Article | Follow @EmilyWFierce

@MichaelGFierce:  Encapsulated #Alzheimers, #Parkinsons-treating growth factors implanted directly in the brain. More from FierceDrugDelivery | Follow @MichaelGFierce

> Apple kicks med tech app developers out of the iCloud. Item

> Edwards profit up 23%, but increased TAVR competition looming. Story

Pharma News

@FiercePharma: Top-read in FiercePharma Thurs: Eli Lilly continues downward spiral in Q3 as generics slam Cymbalta, Evista sales. Story | Follow @FiercePharma

@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. To get it weekly, subscribe. Subscribe | Follow @CarlyHFierce

> Shire poised to succeed as solo act post-AbbVie with solid Q3 earnings. Story

> What does Pfizer's $11B buyback mean for the chances of an AstraZeneca bid? More

> Actavis primed for another deal, or two, or maybe three. Article

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.